Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Afr Health Sci ; 23(2): 128-132, 2023 Jun.
Article in English | MEDLINE | ID: mdl-38223592

ABSTRACT

Setting-Objective: In this study, it was aimed to reveal the incidence of tuberculosis development in patients receiving tumor necrosis factor-alpha (TNF-α) blocker therapy, despite tuberculosis chemoprophylaxis. Design: 520 patients who were receiving anti TNF-α treatment in the last 3 years were evaluated retrospectively. Radiological imaging tuberculin skin test (TST), history of tuberculosis, BCG vaccine, chemoprophylaxis administration, used anti TNF-α drugs were recorded. Results: There were 265(51.0%) of the patients with ankylosing spondylitis (AS), 175(33.7%) with rheumatoid arthritis, 35(6.7%) with Crohn's, 10(1.9%) with ulcerative colitis (UC), 21(4.0%) with psoriatic arthritis, 14(2.7%) with psoriasis vulgaris. In total, 455 (79.6%) patients were given INH prophylaxis. Active tuberculosis development was observed in five patients (4: pulmonary,1: extrapulmonary; 3: UC, 2:AS) who all received anti TNF-α treatment (0.96%), infliximab. Three patients had tuberculosis disease in the 6th month, and the other 2 patients in the 5th and 24th month of their anti TNF-α treatments, and two had 9-month, and 1 had 6-month chemoprophylaxis history. Conclusion: The incidence of tuberculosis development in patients treated with anti TNF-α was found to be higher than the general population. In our country, where tuberculosis is still prevalent, patients receiving Anti TNF-α treatment (especially infliximab) should be carefully questioned and examined about tuberculosis.


Subject(s)
Latent Tuberculosis , Spondylitis, Ankylosing , Tumor Necrosis Factor Inhibitors , Humans , Infliximab/adverse effects , Infliximab/therapeutic use , Latent Tuberculosis/epidemiology , Retrospective Studies , Spondylitis, Ankylosing/drug therapy , Tuberculin Test , Tumor Necrosis Factor Inhibitors/adverse effects , Tumor Necrosis Factor Inhibitors/therapeutic use , Tumor Necrosis Factor-alpha
2.
Jundishapur J Microbiol ; 9(10): e20224, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27942355

ABSTRACT

BACKGROUND: One-third of the world's population is infected with Mycobacterium tuberculosis. Investigation of Toll-like receptors (TLRs) has revealed new information regarding the immunopathogenesis of this disease. Toll-like receptors can recognize various ligands with a lipoprotein structure in the bacilli. Toll-like receptor 2 and TLR-4 have been identified in association with tuberculosis infection. OBJECTIVES: The aim of our study was to investigate the relationship between TLR polymorphism and infection progress. METHODS: Twenty-nine patients with a radiologically, microbiologically, and clinically proven active tuberculosis diagnosis were included in this 25-month study. Toll-like receptor 2 and TLR-4 polymorphisms and allele distributions were compared between these 29 patients and 100 healthy control subjects. Peripheral blood samples were taken from all patients. Genotyping of TLR-2, TLR-4, and macrophage migration inhibitory factor was performed. The extraction step was completed with a Qiagen mini blood purification system kit (Qiagen, Ontario, Canada) using a peripheral blood sample. The genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism. RESULTS: In total, 19 of the 29 patients with tuberculosis infection had a TLR-2 polymorphism, and 20 of the 100 healthy subjects had a TLR-2 polymorphism (P < 0.001). The TLR-4 polymorphism and interferon-γ allele distributions were not statistically correlated. CONCLUSIONS: Toll-like receptor 2 polymorphism is a risk factor for tuberculosis infection. The limiting factor in this study was the lack of investigation of the interferon-γ and tumor necrosis factor-α levels, which are important in the development of infection. Detection of lower levels of these cytokines in bronchoalveolar lavage specimens, especially among patients with TLR-2 defects, will provide new data that may support the results of this study.

3.
Expert Opin Pharmacother ; 17(2): 153-8, 2016.
Article in English | MEDLINE | ID: mdl-26629809

ABSTRACT

UNLABELLED: INTRODUCTION-OBJECTIVE: Despite the availability of national and international guidelines, chronic obstructive pulmonary diseases (COPD) treatment is not always prescribed according to these recommendations. We aimed to see if COPD patients in Turkey have been treated appropriately according to COPD guidelines. METHODS: This is a cross-sectional study carried out in six different chest diseases clinics. The COPD outpatients were categorized by spirometry classification (SC) and the combined classification (CC) of COPD. The treatment protocols were evaluated to check whether they were suitable for both classifications. RESULTS: Overall, 307 patients were included in the study. Of the treatment protocols, 40.4% were suitable for both classifications: 30.9% for CC and 20.8% for SC. A total of 51.8% of the patients were reported to be using an unsuitable therapy for SC and 38.4% for CC. Ninety-eight per cent of the unsuitable treatment was overtreatment. Fifty-eight per cent of the patients were using LABA + LAMA + ICS. Improper ICS usage was identified in 97.1% in CC, 93.1% in SC. The cost savings of all patients in one year would be 17,099$ with an appropriate treatment protocol following COPD guidelines. CONCLUSION: The most common type of inappropriate COPD treatments is overtreatment, generally with ICS. As treatment protocols following COPD guidelines change over time, there is still a low rate of adherence by clinicians in their clinical practice to guideline recommendations. Awareness of these guidelines by pulmonary specialists should be improved.


Subject(s)
Pulmonary Disease, Chronic Obstructive/drug therapy , Adult , Aged , Aged, 80 and over , Cost Savings , Cross-Sectional Studies , Female , Guideline Adherence , Humans , Male , Medical Overuse , Middle Aged , Practice Guidelines as Topic , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/economics , Turkey
4.
Jundishapur J Microbiol ; 8(2): e15612, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25825641

ABSTRACT

BACKGROUND: Acinetobacter baumannii is an opportunistic pathogen, related with nosocomial infections such as bacteremia, urinary tract infections, and ventilator-associated pneumonia. Multidrug resistant (MDR) A. baumannii strains are first line causes of infection, especially in patients hospitalized at intensive care units (ICUs). Infection with MDR A. baumannii strains has a longer duration at ICUs and hospitals. There are studies using molecular methods which can differentiate MDR A. baumannii strains at the clonal level. This helps controlling these resistant strains and prevents their epidemy. OBJECTIVES: The aim of our study was to investigate the antimicrobial susceptibility and clonal relationship between the A. baumannii strains isolated from our ICU. MATERIALS AND METHODS: The identification and antimicrobial susceptibility of 33 A. baumannii strains were performed by automatized Vitek version 2.0. The clonal relationship among A. baumannii strains was analyzed using enterobacterial repetitive intergenic consensus (ERIC) polymerase chain reaction (PCR). RESULTS: A total of 33 A. baumannii strains were included in this study. A. baumannii complex strains were classified into seven clusters based on the fingerprint results. Our results revealed that two main clusters were responsible for the prevalence of A. baumannii complex strains at the ICU. CONCLUSIONS: MDR A. baumannii strains cause an increment in morbidity and mortality, particularly in ICUs. The use of molecular epidemiological methods can help us with the detection of the pathogen and preventing from spreading of these resistant strains.

5.
Wien Klin Wochenschr ; 127(7-8): 256-61, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25595117

ABSTRACT

BACKGROUND: N-acetylcysteine (NAC) has been shown not to alter the clinical outcome in chronic obstructive pulmonary disease (COPD) exacerbations. However, NAC may improve symptoms through its mucolytic effect in the subgroup of patients with increased sputum production. The aims of this study were to determine whether NAC improves symptoms and pulmonary function in patients with COPD exacerbation and increased sputum production. METHODS: This was a placebo-controlled study, where patients with severe COPD and increased sputum production, who were hospitalized for an exacerbation, were included. They were randomized to receive either NAC 200 mg tid or placebo in addition to the usual treatment. RESULTS: Forty-two patients were included and were equally distributed to NAC and placebo groups. The symptoms, namely, ease of sputum production and dyspnea at rest and on exertion significantly improved in both groups; but there was no difference in improvement between NAC and placebo groups (p = 0.96, 0.62, 0.31, respectively). Similarly, forced expiratory volume-one second (FEV1) and PaO2 levels improved significantly in NAC (964 ± 599-1239 ± 543 ml, p < 0.001, and 57.5 ± 14.5-70.5 ± 16.0 mmHg, p < 0.001, respectively) and placebo groups (981 ± 514-1180 ± 535 ml, p < 0.001 and 57.9 ± 14.3-68.7 ± 19.0 mmHg, p < 0.001, respectively), without any difference between the two groups (p = 0.52 and 0.57). There was no difference in the number of exacerbations during the 6-month follow-up period. CONCLUSION: NAC does not have any beneficial effect on clinical outcomes in patients with severe COPD exacerbation associated with increased and/or viscous mucus production.


Subject(s)
Acetylcysteine/therapeutic use , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/drug therapy , Sputum/drug effects , Aged , Double-Blind Method , Expectorants/therapeutic use , Female , Humans , Male , Placebo Effect , Treatment Outcome
6.
Pan Afr Med J ; 17: 49, 2014.
Article in English | MEDLINE | ID: mdl-25018799

ABSTRACT

In this case report we aimed to present a patient with granulocytic sarcomaa, neutropenic fever, ARDS and Pneumocystis jirovecii pneumoniae that was hospitalized in our intensive care unit. The patient recovered and then developed vancomycin resistant enterococci (VRE) bacteremia due to port catheter during follow up. The patient had risk factors for VRE bacteremia and he was administered linezolide without removing the catheter. He was discharged with recovery.


Subject(s)
Bacteremia/complications , Pneumocystis carinii , Pneumonia, Pneumocystis/complications , Respiratory Distress Syndrome/complications , Sarcoma, Myeloid/complications , Vancomycin-Resistant Enterococci , Bacteremia/microbiology , Enterococcus faecium , Gram-Positive Bacterial Infections/complications , Humans , Immunocompromised Host , Male , Pneumocystis carinii/isolation & purification , Pneumonia, Pneumocystis/microbiology , Respiratory Distress Syndrome/microbiology , Sarcoma, Myeloid/microbiology , Vancomycin-Resistant Enterococci/isolation & purification , Young Adult
7.
Article in English | MEDLINE | ID: mdl-24972390

ABSTRACT

BACKGROUND AND OBJECTIVE: To evaluate choroidal thickness using spectral-domain optical coherence tomography (SD-OCT) in patients with obstructive sleep apnea syndrome (OSAS) in comparison to healthy controls. PATIENTS AND METHODS: This observational, comparative study consisted of 35 patients with OSAS and 32 age- and sex-matched controls. The controls did not have systemic or ocular diseases. All study participants underwent complete ophthalmic examination as well as choroidal thickness measurement using a high-speed, high-resolution SD-OCT device. RESULTS: The mean horizontal and vertical choroidal thicknesses, respectively, were 237.84 ± 69.9 µm and 234.97 ± 62.0 µm (P = .654) in patients with OSAS and 244.09 ± 41.2 µm and 241.88 ± 40.9 µm (P = .590) in the healthy controls. The mean choroidal thicknesses were thinner in patients with OSAS, but the difference was not significant (P > .05 for all values). CONCLUSION: No differences in choroidal thickness were found between patients with OSAS and healthy controls.


Subject(s)
Choroid/pathology , Sleep Apnea, Obstructive/pathology , Adult , Aged , Analysis of Variance , Case-Control Studies , Female , Humans , Male , Middle Aged , Polysomnography , Tomography, Optical Coherence/methods
8.
Asian Pac J Cancer Prev ; 14(7): 4365-8, 2013.
Article in English | MEDLINE | ID: mdl-23992004

ABSTRACT

BACKGROUND: Bronchioloalveolar carcinoma (BAC) is considered a subtype of adenocarcinoma of the lung. Recently BAC has been variously termed adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant invasive adenocarcinoma, and invasive mucinous adenocarcinoma. The aim of the study was to analyze and detect prognostic factors of patients with BAC over a 7-year period. MATERIALS AND METHODS: This retrospective single-center study included 44 patients with BAC. The impact on survival of fifteen variables (gender, age, smoking status, cough, dyspnea, hemoptysis, fever, chest pain, sputum, metastasis number, Karnofsky performance status, pT, pN, TNM stage, cytotoxic chemoterapy) were assessed. RESULTS: Median age was 55 years (38-83). Most patients were male (63.6%) and stage IV (59.1%). Twenty-one patients (47.7%) received cytotoxic chemotherapy (platinum-based regimens) for metastatic disease. Objective response rate was 33.3% (4 partial, 3 complete responses). Stable disease was observed in nine in patients (42.8%). Disease progression was noted in 5 (23.8%). The median OS for all patients was 12 months (95%CI, 2.08-22.9 months). Independent predictors for overall survival were: Karnofsky performance status (HR:3.30, p 0.009), pN (HR:3.81, p 0.018), TNM stage (HR:6.49, p 0.012) and hemoptysis (HR:2.31, p 0.046). CONCLUSIONS: Karnofsky performance status, pN, TNM stage and hemoptysis appear to have significant impact on predicting patient survival in cases of BAC.


Subject(s)
Adenocarcinoma, Bronchiolo-Alveolar/mortality , Adenocarcinoma, Bronchiolo-Alveolar/pathology , Adenocarcinoma, Bronchiolo-Alveolar/surgery , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Karnofsky Performance Status , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Prognosis , Retrospective Studies , Survival Rate
9.
J Cardiothorac Vasc Anesth ; 27(6): 1267-70, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23953869

ABSTRACT

OBJECTIVES: In elderly patients with mild cognitive impairment, noncompliance with respiratory exercises, ineffective expectoration, reluctance in mobilization, and difficulty in learning the use of drugs such as inhalers were observed in the early postoperative period after coronary artery bypass graft surgery. It was hypothesized that respiratory complications may be more frequent in these patients, and so the postoperative respiratory complications in patients with preoperative mild cognitive impairment were compared with the postoperative respiratory complications of a control group. DESIGN: A prospective cohort control. SETTING: A university hospital. PARTICIPANTS: Patients undergoing elective coronary artery bypass graft surgery. INTERVENTIONS: Investigators separated 48 patients>70 years old who were scheduled for elective coronary artery bypass graft surgery into two groups: patients with preoperative mild cognitive impairment (group A, n = 25) and patients with no cognitive impairment (control group; group B, n = 23). The patients' cognitive status was evaluated preoperatively by the Montreal Cognitive Assessment test. MEASUREMENTS AND MAIN RESULTS: Pulmonary functions and respiratory complications were evaluated via chest x-rays and spirometry tests preoperatively and postoperatively. A significant difference was observed between the groups, particularly with regard to atelectasis and prolonged ventilation (p<0.001 and p<0.05). No significant impairment was observed in the spirometry tests of the control group. However, a significant deterioration was observed in the postoperative spirometry tests of patients with preoperative mild cognitive impairment. CONCLUSIONS: This study suggested that mild cognitive impairment was associated with pulmonary complications after coronary artery bypass graft surgery.


Subject(s)
Cognitive Dysfunction/complications , Coronary Artery Bypass/adverse effects , Lung Diseases/etiology , Postoperative Complications/etiology , Aged , Anesthesia , Female , Humans , Lung Diseases/epidemiology , Male , Neuropsychological Tests , Pleural Effusion/drug therapy , Postoperative Complications/epidemiology , Predictive Value of Tests , Prospective Studies , Risk Factors , Spirometry , Vital Capacity
10.
Respir Med ; 107(3): 448-50, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23290153

ABSTRACT

A 67-year-old woman was referred to our department for further evaluation of her abnormal, chest radiogram. Thorax computed tomography revealed a well-circumscribed, round mass in the middle lobe of the right lung. A thoracotomy was performed and pulmonary sclerosing hemangioma was diagnosed. We herein present a rare tumor of the lung.


Subject(s)
Pulmonary Sclerosing Hemangioma/diagnostic imaging , Aged , Female , Humans , Pulmonary Sclerosing Hemangioma/pathology , Pulmonary Sclerosing Hemangioma/surgery , Thoracotomy , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...